Clicky

RAPT Therapeutics, Inc.(RAPT)

Description: RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Disease Pharmacy Immunology Tumor Treatment Of Cancer Inflammatory Diseases Specialty Drugs Small Molecule Therapies Immune Response

Home Page: www.rapt.com

RAPT Technical Analysis

561 Eccles Avenue
South San Francisco, CA 94080
United States
Phone: 650 489 9000


Officers

Name Title
Dr. Brian Russell Wong M.D., Ph.D. CEO, Pres & Director
Mr. Rodney K. B. Young CFO, Principal Accounting Officer & Sec.
Dr. William Ho Chief Medical Officer
Steve Young Ph.D. VP of Technology
Dr. Dirk G. Brockstedt Ph.D. Chief Scientific Officer
Ms. Gwen R. Carscadden Chief HR Officer
Dr. Paul Kassner Sr. VP of Quantitative & Computational Biology
Dr. David Wustrow Sr. VP of Drug Discovery & Preclinical Devel.
Ms. Jennifer Nicholson Sr. VP of Regulatory Affairs & Quality Assurance

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.0609
Price-to-Sales TTM: 266.1551
IPO Date: 2019-10-31
Fiscal Year End: December
Full Time Employees: 94
Back to stocks